F614 News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from F614. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In F614 Today - Breaking & Trending Today

Ensysce Biosciences, Inc.: Ensysce Biosciences Announces Critical Step in Human Abuse Potential Study of PF614 With Database Lock

Company Remains on Track to Report Results the End of MarchSAN DIEGO, CA / ACCESSWIRE / February 28, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage biotech ....

Dennis Riedl , Lynn Kirkpatrick , Ensysce Biosciences , Shannon Devine , Ensysce Biosciences Inc View , Vince Clinical Research , Ensysce Biosciences Inc , Mz Group North America , Ensysce Biosciences Company Contact , Company Remains , Report Results , Human Abuse Potential , Trypsin Activated Abuse Protection , Vince Clinical , Abuse Deterrent , Multi Pill Abuse Resistance , Private Securities Litigation Reform Act , Biosciences Investor Relations Contact , Inc View ,

Ensysce Biosciences, Inc.: Ensysce Biosciences Announces FDA Guidance on the Clinical Development Pathway for PF614

~ Acute pain indication may be appropriate, with potential to significantly shorten development path ~SAN DIEGO, CA / ACCESSWIRE / November 14, 2022 / Ensysce Biosciences Inc. ("Ensysce" or the "Company") ....

Lynn Kirkpatrick , Ensysce Biosciences , Shannon Devine , Ensysce Biosciences Inc View , Ensysce Biosciences Inc , Ensysce Biosciences Company Contact , Trypsin Activated Abuse Protection , Multi Pill Abuse Resistance , Biosciences Company Contact , Biosciences Investor Relations Contact ,

Ensysce Biosciences, Inc.: Ensysce Biosciences Announces Positive Topline Results of Clinical Study Evaluating Human Abuse Potential of Intranasal Administration of PF614, a TAAP Abuse-Deterrent Oxycodone Extended-Release Product

~ Announces Timing of Corporate Update Call ~SAN DIEGO, CA / ACCESSWIRE / October 31, 2022 / Ensysce Biosciences Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage biotech ....

Lynn Kirkpatrick , Ensysce Biosciences , Shannon Devine , Ensysce Biosciences Inc View , Ensysce Biosciences Inc , Ensysce Biosciences Company Contact , Announces Timing , Corporate Update Call , Trypsin Activated Abuse Protected , Abuse Deterrent Formulations , Abuse Potential , Corporate Update , Trypsin Activated Abuse Protection , Multi Pill Abuse Resistance , Biosciences Company Contact , Biosciences Investor Relations Contact ,

Ensysce Biosciences Inc: Ensysce Biosciences and Quotient Sciences Announce a Partnership on the Development and Clinical Testing of Ensysce's PF614-MPAR, a Novel Opioid Designed to Prevent Abuse and Overdose

Partnership further expedites Ensysce's development pipeline NOTTINGHAM, England, Aug. 31, 2022 /PRNewswire/ Ensysce Biosciences, Inc., a clinical-stage biotech company applying transformative ....

Mark Egerton , Lynn Kirkpatrick , Ensysce Biosciences , Prnewswire Ensysce Biosciences Inc , Quotient Sciences , Translational Pharmaceutics , Biosciences San Diego , Trypsin Activated Abuse Protection , Multi Pill Abuse Resistance ,

Ensysce Biosciences, Inc.: Ensysce Biosciences Announces Completion of Clinical Portion of Human Abuse Potential Trial PF614-103

Completion of Clinical Portion Represents Critical Milestone Towards CommercializationNasal Opioid Abuse Being Explored for PF614Data From Trial Expected in September 2022SAN DIEGO, CA / ACCESSWIRE / August ....

United States , Lynn Kirkpatrick , Ensysce Biosciences , Glen Apseloff , Shannon Devine , Ohio Clinical Trials Inc , Ensysce Biosciences Inc , Mz Group North America , Ensysce Biosciences Company Contact , Opioid Abuse Being Explored , From Trial Expected , Active Controlled Crossover Study , Intranasal Abuse Potential , Immediate Release Oxycodone , Non Dependent Recreational Opioid User , Ohio Clinical Trials , Abuse Potential , Abuse Deterrent , Nily Osman , Chief Medical Officer , Maximum Drug Liking , Take Drug Again , Drug Liking , Trypsin Activated Abuse Protection , Multi Pill Abuse Resistance , Private Securities Litigation Reform Act ,